– Additional Phase 3 PURPOSE data reinforce the safety profile of twice-yearly Yeztugo® as an effective HIV prevention option across diverse populations –
– New data show higher treatment satisfaction after switching from IM CAB+RPV to Biktarvy® –
– New research reaffirms Veklury® in high-risk COVID-19 populations and obeldesivir in emerging pathogens –
Read the full company press release here.
Source : Gilead Sciences, Inc.